Single agonists of sst1, 2, and 5 affected both tumor growth and neoangiogenesis via the inactivation of ERK1/2 and the upregulation of p27Kip1, representing a common intracellular pathway for all the receptors. Here, CDKN1B is linked to neoplasm.